Pirarubicin


Concise Prescribing Info
Indications/Uses
Breast cancer.
Dosage/Direction for Use
Adult : IV 25-50 mg/m2 3-4 wkly.
Dosage Details
Intravenous
Breast cancer
Adult: 25-50 mg/m2 BSA every 3-4 wk, to be given as inj over 5-10 minutes into a rapidly-flowing infusion of glucose 5%.
Contraindications
Cardiac disease. Pregnancy.
Special Precautions
Extravasation. Monitor cardiac function and blood counts. Hepatic impairment. Not to be given IM or SC. Check left ventricular ejection fraction before every course for doses >600 mg/m2.
Adverse Reactions
Moderate to severe nausea, vomiting and stomatitis; facial flushing, conjunctivitis and lachrymation; alopoecia; red coloration of urine; hypersensitivity reactions and hyperuricaemia.
Potentially Fatal: Pronounced bone-marrow suppression (dose-limiting), cardiac toxicity.
Drug Interactions
Reduced absorption of digoxin tablets. Increased risk of low WBC counts when used with clozapine. Increased risk of cardiotoxicity when used with mitomycin.
Action
Description: Pirarubicin, a structural analogue of doxorubicin and with similar properties, forms stable complexes with DNA and interferes with nucleic acid synthesis.
Disclaimer: This information is independently developed by MIMS based on Pirarubicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in